PCN56 Brentuximab Vedotin PLUS CHP in Frontline Systemic Anaplastic Large Cell Lymphoma (SALCL): Adjusted Estimates of Efficacy and Cost-Effectiveness Removing the Effects of Retreatment with Brentuximab Vedotin
Abstract
Authors
H. Cranmer D. Trueman F. Woodcock E. Evers T. Podkonjak